Global Small Cell Lung Cancer (SCLC) Therapeutics Market, By Treatment Type (Chemotherapy, Targeted Therapy, Others), Route of Administration (Oral, Intravenous, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Size
The global small cell lung cancer (SCLC) therapeutics market is expected to witness significant growth during the forecast period. The factors propelled the growth of Small Cell Lung Cancer (SCLC) therapeutics market are rise in cases of small cell lung cancer (SCLC) across the world and promising pipeline drugs. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global small cell lung cancer (SCLC) therapeutics market in the forecast period 2022-2029. The expected CAGR of global small cell lung cancer (SCLC) therapeutics market is tend to be around 10.0% in the mentioned forecast period. The market was valued at USD 10 billion in 2021, and it would grow upto USD 21.44 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Small cell lung cancer (SCLC) is termed as oat cell carcinoma is a most aggressive type of lung cancers which accounted around 10% to 15% of all lung cancers. In small cell lung cancer (SCLC) abnormal growth of cells originates from the tissues of the in the breathing tubes where it grows very rapidly and form large tumors. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period
Small Cell Lung Cancer (SCLC) Therapeutics Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment Type (Chemotherapy, Targeted Therapy, Others), Route of Administration (Intravenous, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), Bayer AG (Germany), Lilly (U.S.), Merck & Co., Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), CLOVIS ONCOLOGY (U.S.), Johnson & Johnson Private Limited (U.S.)
|
|
Market Opportunities
|
|
Global Small Cell Lung Cancer (SCLC) Therapeutics Market Dynamics
Drivers
- Increase in Cancer Cases
The rise in cancer cases globally boosts the global small cell lung cancer (SCLC) therapeutics market in the forecast period As per the reports of the American Cancer Society Statistics in 2016, majority of cases of SCLC mostly occur in individuals between the age group of 60-80 years with an estimated global death rate being 30,000 per year. In addition to this, as per the reports of WHO, lung cancer is the second most dominant cancer in men and women causing 1.59 million deaths in 2012. This boost the market growth.
- Rising Demand for Oral Drugs
Oral drugs is expected to increase the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.
Opportunities
- Patent Expiration Encourages New Launches
Patent expiration of old companies can make better opportunities for the new market players. The adoption of combination therapies is a significant factor that contributes to the growth of the small cell lung cancer (SCLC) therapeutics market. Further, R&D fundings are an add-on to the market.
- Development of Diversified Treatments
Treatments such as chemotherapy and radiation therapy are given to the patient to treat early stage of small cell lung cancer. These offer great benefits to the patients. For instance, radiation therapy is given to patients to shrink tumor cells as well as to relieve symptoms such as cough, trouble swallowing, bleeding, and shortness of breath. Techniques such as three-dimensional conformal radiation therapy (3D-CRT) and intensity modulated radiation therapy (IMRT) are the two types of radiation methods that are widely used in the treatment.
- Rising Healthcare Awareness
Awareness among patients as well as healthcare providers about the incidence of small cell lung cancer (SCLC) is on the rise. Patients and doctors are now more actively participating in learning about the therapies that are available for the treatment of these severe diseases. This is one of the most important drivers in the market. This creates more opportunity in the market.
Restraints/Challenges
- Lack of Skilled Professionals
Lack of trained professionals who are unaware of the knowledge of the treatment methods for this disease could curb the growth of the global small cell lung cancer (SCLC) therapeutics market over a forecast period.
- Increasing Cost Of Treatments
The huge expenditure required for the treatment methods surely hamper the market growth. Many of the treatments involved in this disease require high cost and thus at times gets difficult for many people, especially the ones in the rural areas. Thus, this can act as a major hindrance factor for the market.
This global small cell lung cancer (SCLC) therapeutics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global small cell lung cancer (SCLC) therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Small Cell Lung Cancer (SCLC) Therapeutics Market Scope
The global small cell lung cancer (SCLC) therapeutics market is segmented on the basis of treatment type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment Type
- Chemotherapy
- Targeted Therapy
- Others
Route of Administration
- Intravenous
- Others
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Small Cell Lung Cancer (SCLC) Therapeutics Market Regional Analysis/Insights
The global small cell lung cancer (SCLC) therapeutics market is analysed and market size insights and trends are provided by treatment type, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global small cell lung cancer (SCLC) therapeutics market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific is expected to have the highest market growth due to the presence of key generic pharmaceuticals companies in this region and rise in government initiatives and awareness.
North America dominates the market due to the increase prevalence of small cell lung cancer (SCLC) and large availability of treatment options.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Small Cell Lung Cancer (SCLC) Therapeutics Market Share Analysis
The global small cell lung cancer (SCLC) therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global small cell lung cancer (SCLC) therapeutics market.
Key players operating in the global small cell lung cancer (SCLC) therapeutics market include:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Lilly (U.S.)
- Merck & Co., Inc. (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- CLOVIS ONCOLOGY (U.S.)
- Johnson & Johnson Private Limited (U.S.)
SKU-